Immunotherapy for Squamous Non-Small Cell Lung Cancer
The immune checkpoint inhibitor nivolumab has been shown in the CheckMate 017 trial to lead to better response rates, survival, and better tolerability than docetaxel (Taxotere) chemotherapy. But can ...
Author: cancergrace
Added: 06/17/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Taxotere